PTO/SB/61 (7-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

NOITKE	FOR	<b>REVIVAL</b>	OF AN	I APPLICATION	FOR	<b>PATENT</b>	<b>ABANDONED</b>
JNAVOID.	ABLY	<b>UNDER 3</b>	7 CFR	1.137(a)			

Docket Number (Optional) 4673120/4650

First named inventor: Kreamer

Group Art Unit: 1614

JUN 15 2000

Application Number: 08/071,052

Examiner: Criares

OFFICE OF PETITIONS

DEPUTY A/C PATENTS

Filed: June 4, 1993

Title: Aspirin and Vitamin and/or Trace Element Compositions for the Amelioration and Treatment of Vascular Disease

Attention: Office of Petitions

**Assistant Commissioner for Patents** 

**Box DAC** 

Washington, D.C. 20231

NOTE: If information or assistance is needed in completing this form, please contact Petitions

Informationat(703)305-9282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

### APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- Petition fee; (1)
- (2)Reply and/or issue fee;
- Terminal disclaimer with disclaimer fee -- required for all utility and plant applications filed (3)before June 8, 1995, and for all design applications; and
- (4) Adequate showing of the cause of unavoidable delay

4	 _		٠.		•	
	re	211	rıc	חו	fe	e

<b>✓</b> small entity - fee \$ <u>55.00</u> (37 CFR 1.17(I)).
small entity statement enclosed herewith.
small entity statement previously filed.
other than small entity - fee \$ (37 CFR 1.17(I)).

2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action in	52 55.00 (
the form of Response to Restriction Requirement	(identify the இச் o இep இ):
has been filed previously on November 30, 1999	
is enclosed herewith.	09/20/2000 00000004 2000 LGIBBS
B. The issue fee of \$	720, 000 1 8ber 1
has been paid previously on	
is enclosed herewith.	date: VVAN1 09/20 Name

[Page 1 of 3]

Burden Hour Statement: This form is estimated to take 1.0 hours to complete. Time will vary depending upon the needs 政机能 in hid yal case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, 可能的 and Edemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant commissioner for Patents, Washington, DC 20231.

으

06/14/2000 WHM11 00000004 08071052

PTO/SB/61 (7-99)

Approved for use imough 09/30/2000. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION UNAVOIDABLY UNDER 37 CFR 1.137(a)	ON FOR PATENT ABANDONED			
3. Terminal disclaimer with disclaimer fee				
Since this utility/plant application was filed	d on or after June 8, 1995, no terminal disclaimer is required.			
	(37 CFR 1.20(d)) of \$ 55.00 for a small entity or \$ period equivalent to the period of abandonment is enclosed			
	lelay, and that the entire delay in filing the required reply from grantable petition under 37 CFR 1.137(a) was unavoidable, is			
June 8, 2000 Date	Ceth Herri Signature			
	Signature			
Telephone Number: (515) 288-2500	Kent A. Herink			
DAN LOSENDENS	Typed or printed name			
(41) 743,000	666 Walnut Street, Suite 2500			
DAN LOSENDENT	Address			
	Des Moines, Iowa 50309			
Enclosures: Fee Payment  Reply  Terminal Disclaimer Form				
Small Entity Status Form				
Additional sheets containing sta	atements establishing unavoidable delay			
CERTIFICATE OF MAILIN	G OR TRANSMISSION [37 CFR 1.8(a)]			
I hereby certify that this correspondence is being:				
first class mail in an envelope addres Washington, D.C. 20231.	Service on the date shown below with sufficient postage as used to: Assistant Commissioner for Patents, Box DAC, in below to the Patentand Trademark Office at (703) 308-6916.			
	TIMORHY G. HORMEHER  Typed or printed name of person signing certificate			
	Typed of printed frame of person signing certificate			

# PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNAVOIDABLY UNDER 37 CFR 1.137(a)

NOTE: The following showing of the cause of unavoidable delay must be signed by all applicants and by any other party who is presenting statements concerning the cause of delay.

Typed or printed name


On November 5, 1999, we received an Office action with the cover sheet missing (PTO-90C). The response to the action received on November 5 was a restriction requirement and was filed via facsimile on November 30, 1999. Operating with the understanding that the mailing date was early November 1999, the November 30 filing was thought to be a timely response to the Office action. However, on May 12, 2000, we received a Notice of Abandonment stating that the response was late and without a Petition to Extend the time to Answer and the required fee. On June 7, 2000, we learned from Examiner Criares that the actual mailing date of the Office action was August 19, 1999. As such, the time to respond to the action had already expired by the time we received it in November.

(In the space provided below, please explain in detail the reasons for the delay in filing a proper reply)

Based on the foregoing, the entire delay in replying to the original action was unavoidable due to the unforeseen fault or imperfection of the U.S. Postal Service, or the U.S. PTO, in delivering and/or mailing the original action.

All actions in response to the Office action were timely and diligent and did not lead to the abandonment.

(Please attach additional sheets if additional space is necessary)



PTO/SB/69 (12-97)

# **PETITION ROUTING SLIP**

(Find the petition from the list and check the box in the heading above the petition)

A CALL MANY COMMENT OF THE CALL OF THE CAL		
Со	mplete if Known	سام ۱۱۵ سال دیا ا
Application Number	08/071,052	CIEVEIVEL
Filing Date	June 4, 1993	
First Named Inventor	Kreamer	JUN 1-5-2000
Group Art Unit	1614	0013 1 3 2000
Examiner Name	Criares	OFFICE
Attorney Docket Number	4673120/4650	DEPLIEVACE PATENT

	PETITIONS DECIDED BY PETITIONS OFFICE		
302 303 304 305 306 307 308 309 310 311 312 313 314 315 399 408 411 412 501	Relating to Public Use Proceedings (37 CFR 1.292) To make application special - prospective manufacture (37 CFR 1.102, MPEP 708.02) To make special - infringement (37 CFR 1.102, MPEP 108.02) Relating to the Filing/Issuance of Divisional Reissue (37 CFR 1.177) To waive or suspend rules (37 CFR 1.183) To expunge a paper from patent application or patent file (37 CFR 1.59) Withdrawal of Attorney (37 CFR 1.36) For access to application except re proceedings before Board (37 CFR 1.14, MPEP 103,104) Relating to Small Entity (37 CFR 1.28) Relating to Small Entity (37 CFR 1.181-1.183) For correction of inventorship for applications - no filing date (37 CFR 1.48) For correction of inventorship for applications (37 CFR 1.48) For filing application without one or more inventors (37 CFR 1.47) For extension of time without fee in cases in Application Division (37 CFR 1.136(b)) For matters before A/C for Patents - not specified Relating to a filing date under 35 USC 111& 37 CFR 1.53 Filing date for application filed by Express Mail (37 CFR 1.10) Filing date for lost application - unavoidable delay (37 CFR 1.137(a)) To revive an abandoned application - unintentional abandonment (37 CFR 1.137(b))	504 505 506 507 508 515 516 519 523 525 526 527 528 530 531 532 533 534	To invoke supervisory authority - re patent examining operations (37 CFR 1.181) To withdraw from issue after payment of issue fee (37 CFR 1.313(b)(1-4)) To withdraw from issue after payment of issue fee (37 CFR 1.313(b)(1-4)) To withdraw from issue after payment of issue fee (37 CFR 1.313(b)() or abandon application in favor of continuing application To enter priority papers after Issue Fee payment (37 CFR 1.55(a)) To defer issuance of patent (37 CFR 1.314) To invoke supervisory authority - re Office of Admin. (37 CFR 1.181) To waive/suspend rules re patent mailers in Office of Admin. (37 CFR 1.183) To decide matters before Deputy A/C for Patents under 37 CFR 1.182 To review refusal to accept & record maintenance fee - application filed on or after 8/27/82 (37 CFR 1.377) To issue patent in the name of the Assignee (37 CFR 1.334(c)) To withdraw a holding of abandonment (37 CFR 1.181) To order a Commissioner-initiated Reexamination proceeding (37 CFR 1.520) To convert Provisional Application To reinstate abandoned Provisional Application PCT petition-unitentional To accept unavoidably delayed payment of maintenance fee (37 CFR 1.378 (b))
	PETITIONS DECIDED BY THE GROUP DIRECTOR		
602 603 604 605 606 607 608 610 611 612 613 614 615	To make application special on ground of age or health (37 CFR 1.102, MPEP 708.02) 708.02) To make special - continuity of earlier application (37 CFR 1.102, MPEP 708.02) To make special - environment quality program (37 CFR 1.102, MPEP 708.02) To make special - environment quality program (37 CFR 1.102, MPEP 708.02) To make special - Seclerated examination (37 CFR 1.102, MPEP 708.02) To make special - Recombinant DNA (37 CFR 1.102, MPEP 708.02) To make special for reasons not provided for in codes 601-606 (37 CFR 1.102, MPEP 708.02) To make special for reasons not provided for in codes 601-606 (37 CFR 1.102, MPEP 708.02) To reopen prosecution after Board decision (37 CFR 1.198) For review of final restriction requirement (37 CFR 1.181 not specified in codes Relating to the prematureness of final rejection (37 CFR 1.181, MPEP 706.07(c)) Relating to the refusal to enter an amendment (37 CFR 1.181, MPEP 706.07(c)) Relating to a requirement to cancel new matter from application (37 CFR 1.181. MPEP 711.03) Relating to formal sufficiency/propriety of affidavits (37 CFR 1.131, 1.132, 1.608, MPEP 715.07) To institute an interference (37 CFR 1.606) Relating to refusal to enter an amendment under 37 CFR 1.312	619 620 621 622 623 625 626 627 628 630 631 632 633 634 635 636 637	For concurrent Ex parte and Inter parte proceedings (37 CFR 1.212) For return of original oath of patent application (MPEP 604.04(a)) For extension of time (37 CFR 1.136(b)) For interview after Notice of Allowance mailed (MPEP 713.10) Conceming appeal application before transfer of jurisdiction to Board (MPEP 1206) For second or subsequent suspension of action (37 CFR 1.103, MPEP 709) To reinstate Appeals dismissed in Group From denial of reexamination request (37 CFR 515(c)) To enter an amendment after payment of Issue Fee (37 CFR 1.312(b)) From refusal to issue a Certificate of Correction (37 CFR 1.181, MPEP 1480 -1485) For withdrawal of attomey from application pending in group (37 CFR 1.36) For extension of lime in a reexamination (37 CFR 1.565(c), MPEP 2283) To effect a second conversion of inventorship (37 CFR 1.48, MPEP 201.03) Superconductivity To correct inventorship in a patent not in interference (37 CFR 1.324, MPEP 1481) To change inventorship in an application (37 CFR 1.48) To change inventorship in a patent (37 CFR 1.48) To withdraw from Issue before payment of an Issue fee (37 CFR 1.313(a)) For matters before Group Director - not specified
702	PETITIONS DECIDED BY BOARD OF PATENT APP To exercise supervisory authority re action by examiner/examiner-in-chief (37 CFR 1.644) To accept belatedly filed copies of interference settlement agreements (35 USC 135(c), 37 CFR 1.666(c)) For withdrawal of attorney in proceeding under 37 CFR 1.201 - 1.288 (37 CFR 1.36) For access to a settlement agreement under 35 USC 135(c) (37 CFR 1.666(b)) For access to an application in proceedings before the Board (37 CFR 1.14(e)) From a refusal to issue a Certificate of Correction (37 CFR 1.322, 1.323) To correct errors in inventorship (37 CFR 1.324) For extension of time to file amendment under 37 CFR 1.196(b) (37 CFR 1.136) To make an application before the Board special (37 CFR 1.102) For extension of time to file supplemental Reply Brief (37 CFR 1.136)	711 712 713 714 799 801 802 803 804 805	To assign particular members to hearing or to request augmented panel (35 USC 7) To decide miscellaneous questions in proceedings under 37 CFR 1.601-1.688
	PETITIONS DECIDED BY SPECIAL LAWS (SECURI	ΤY	AND GOVERNMENT INTEREST MATTERS)
902	Under 42 USC 2182 Under 42 USC 2457 Under 35 USC 184		Under 35 USC 267 To consider/review security or Government interest matters - not specified
	PETITIONS DECIDED BY THE SOLICITOR		
951 952	Petitions for extension of time in court matters 35 USC 142, 145, 146 Petitions relating to ex parte questions in cases before the Court of Appeals for		Requests filed under the Freedom of Information Act Not specified







# UNITED STATE DEPARTMENT OF COMMERCE

Patent and Trad mark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

FIRST NAMED INVENTOR

08/071,052

06/04/93

KREAMER

467312465

BROWN, KOEHN & SHORS

666 WALNUT ST., STE. 2500

DES MOINES IA 50309

EXAMINER

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

**RECEIVED** 

MAY 1 2 2000

DAVIS, BROWN, KOEHN, SHORS & ROBERTS, P.C.



Notice of Abandonment Jun 1 3 2000

Application No.

Applicant(s)

08/071,052

xaminer

Theodore J. Criares

Group Art Unit 1614

Th	is application is abandoned in view of:
	applicant's failure to timely file a proper response to the Office letter mailed on
	A response (with a Certificate of Mailing or Transmission of) was received on , which is after the expiration of the period for response (including a total extension of time of
	month(s)) which expired on
	A proposed response was received on, but it does not constitute a proper response to the final rejection.
	(A proper response to a final rejection consists only of: a timely filed amendment which places the application in condition for allowance; a Notice of Appeal; or the filing of a continuing application under 37 CFR 1.62 (FWC)).
	☐ No response has been received.
	applicant's failure to timely pay the required issue fee within the statutory period of three months from the mailing date of the Notice of Allowance.
	The issue fee (with a Certificate of Mailing or Transmission of) was received on
	The submitted issue fee of \$ is insufficient. The issue fee required by 37 CFR 1.18 is \$
	The issue fee has not been received.
	applicant's failure to timely file new formal drawings as required in the Notice of Allowability.  Proposed new formal drawings (with a Certificate of Mailing or Transmission of) were received on
	The proposed new formal drawings filed are not acceptable.
	No proposed new formal drawings have been received.
, 	the express abandonment under 37 CFR 1.62(g) in favor of the FWC application filed on
	the letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or all of the applicants.
, j	the letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFR 1.34(a)) upon the filing of a continuing application.
(-)	the decision by the Board of Patent Appeals and Interferences rendered on and because the period for seeking court review of the decision has expired and there are no allowed claims.
X	the reason(s) below:
	Applicant's amendment filed December 1, 1999 arrived late without a Petition to Extend the time to Answer and the required fee. It is suggested that the applicant file a Petition to Revive this application with a declaration as to the facts and supporting documentation.

PODORE J. CRIARES RIMARY EXAMINER ART UNIT 1614

In re Application of	)	
Kreamer	)	Group Art Unit 1614
	)	
Serial No. 08/071,052	)	<b>Examiner Crirares</b>
Filed: June 4, 1993	)	
For: ASPIRIN AND VITAMIN AND/OR	. )	
TRACE ELEMENT COMPOSITIONS	)	
FOR THE AMELIORATION AND	)	
TREATMENT OF VASCULAR DISEAS	E)	

# RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Box Non-Fee Amendment Washington, D.C. 20231

Dear Sir:

In the matter of the above-identified application for United States Letters Patent and in response to the Office Action believed to have been mailed on November 1, 1999 (there being no mailing date identified on the Paper and receiving no response to telephone messages left with Examiner Criares), which was a restriction requirement. This election is made with traverse.

### <u>AMENDMENT</u>

Kindly add new claims 27 - 29 as follows:

- 27. A medicament for reducing atherosclerotic plaque formation at sites of endothelial damage in humans through the reduction of cholesterol incorporation into the endothelium comprising:
  - (a) aspirin orally administered in a dose effective to block prostaglandin function in platelets sufficiently to reduce the

- ability of platelets to go the site of the endothelial damage and recruit other cells to assist in thrombosis; and
- (b) a vitamin orally administered in a dose effective to reduce the migration of cholesterol into the endothelium, wherein said multivitamin comprises at least one vitamin selected from the group including niacin, vitamin C, vitamin E, vitamin A, and vitamin B<sub>6</sub>.
- 28. A medicament as defined in claim 27, wherein said multivitamin contains between about 10 percent and 200 percent of the United States Recommended Daily Allowance of at least one vitamin selected from the group consisting of vitamin A, vitamin B<sub>6</sub>, vitamin C, vitamin E, and niacin.
- 29. A medicament as defined in claim 27, wherein said effective dose of aspirin is between about 20 milligrams and about 325 milligrams of aspirin per day.

#### <u>REMARKS</u>

The Examiner made a restriction requirement under 35 U.S.C. 121, asserting that the claims were drawn to a synergistic combination even though the claims 11-26 currently pending in the application were all method claims directed to a method of ameliorating or treating atherosclerosis. It is believed that the method claims and composition of matter claims inserted by the foregoing amendment comprise a single inventive concept that may all properly be presented in a single application and that the

restriction requirement will lead to an undue multiplication of patent applications with the concomitant burden on applicant in fees and expenses of duplicative prosecution. In any event, three composition of matter claims 27 – 29 have been added to the application and are provisionally elected.

No mailing date was provided on the restriction requirement and a telephone messages left to Examiner Criares asking for the mailing date were not returned. Based on the receipt date of November 5, it is not believed that the mailing date was earlier than November 1, 1999, and so this response is believed to be timely.

Respectfully submitted,

		Kent A. Hepin
Date:	11/30/99	By:
		Kent A Herink

Kent A. Herink
Registration No. 31,025
DAVIS, BROWN, KOEHN,
SHORS & ROBERTS, P.C.
666 Walnut St., Suite 2500
Des Moines, Iowa 50309
Telephone: (515) 288-2500

ATTORNEYS FOR APPLICANT

## CERTIFICATE OF FACSIMILE FILING

I hereby certify that this correspondence is being transmitted by facsimile to the 1600 Group Receptionist at facsimile number 703-308-2742 on November 30, 1999.

Kent A. Hepin

Kent A. Herink



Office Action Summary

olication No. 08/071,052 Applicant(s)

Kreamer

Examiner

Theodore J. Criares

Group Art Unit 1614



X Responsive to communication(s) filed on Sep 16, 1998	9 .
This action is FINAL.	
Since this application is in condition for allowance exce in accordance with the practice under Ex parte Quayle	ept for formal matters, prosecution as to the merits is closed , 1935 C.D. 11; 453 O.G. 213.
is longer, from the mailing date of this communication. Fe	set to expire
Disposition of Claims	
X Claim(s) 11-26	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
Claim(s)	
Claim(s)	
	are subject to restriction or election requirement.
Application Papers	
: See the attached Notice of Draftsperson's Patent D	rawing Review, PTO-948.
The drawing(s) filed on is/are	objected to by the Examiner.
The proposed drawing correction, filed on	is Capproved Cdisapproved.
The specification is objected to by the Examiner.	
The oath or declaration is objected to by the Examin	ner.
Priority under 35 U.S.C. § 119	
Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d).
All Some* None of the CERTIFIED co	pies of the priority documents have been
received.	
received in Application No. (Series Code/Series	al Number)
$\square$ received in this national stage application from	m the International Bureau (PCT Rule 17.2(a)).
*Cartified copies not received:	
Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
Attachment(s)	
☐ Notice of References Cited, PTO-892	
Information Disclosure Statement(s), PTO-1449, Pa	per No(s)
☐ Interview Summary, PTO-413	
☐ Notice of Draftsperson's Patent Drawing Review, P	ГО-948
☐ Notice of Informal Patent Application, PTO-152	
	/ O. T. T. T. T. C. I. G. I. C.
SEE OFFICE ACTION	I ON THE FOLLOWING PAGES

Art Unit: 1614

The final rejection of May 18, 1994 is withdrawn and prosecution is reopened.

Restriction to one invention is required under 35 U.S.C.

121.

The claims are drawn to a synergistic effect as taught by applicants at page 4, of the specification. Applicants are required to (1) elect a single disclosed synergistic combination of specific compounds even though the requirement be traversed and (2) to add a claim directed to that specific combination of compounds since none of applicants claims 11-26 claim a synergistic combination.

The restriction is deemed proper due to the fact that unrelated combinations of compounds yielding synergistic effects are inherently unpredictable and are hence capable of supporting separate and distinct patents.

It is also noted that one specific synergistic combination of two compounds is known to be chemically distinct from another specific synergistic combination of two compounds and reference to one combination would not necessarily be a reference against the other combination under 35 U.S.C. 103.

BEST AVAILARIE COPY

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Criares whose telephone number is (703) 308-4607.

THEODORE J. CRIARES
PRIMARY EXAMINER
GROUP-1900

REST AVAILABLE COPY